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AbstrACt
Objectives Budesonide/formoterol (BF) Spiromax® is an 
inhaled corticosteroid/long-acting β2-agonist fixed-dose 
combination (FDC) inhaler, designed to minimise common 
inhaler errors and provide reliable and consistent dose 
delivery in asthma and chronic obstructive pulmonary 
disease (COPD). We evaluated non-inferiority of BF 
Spiromax after changing from another FDC inhaler, 
compared with continuing the original inhaler.
Methods Patients with asthma and/or COPD who 
switched to BF Spiromax were matched (1:3) with 
non-switchers. Data were obtained from the Optimum 
Patient Care Research Database and Clinical Practice 
Research Datalink in the UK. The primary end point was 
the proportion of patients achieving disease control (using 
the risk domain control (RDC) algorithm); secondary end 
points were: exacerbation rate, short-acting β2-agonist 
(SABA) use and treatment stability (achieved RDC; no 
maintenance treatment change). Non-inferiority was 
defined as having 95% CI lower bound above −10%, using 
conditional logistic regression and adjusted for relevant 
confounders.
results Comparing 385 matched patients (asthma 253; 
COPD 132) who switched to BF Spiromax with 1091 
(asthma 743; COPD 348) non-switchers, non-inferiority 
of BF Spiromax in RDC was demonstrated (adjusted 
difference: +6.6%; 95% CI –0.3 to 13.5). Among patients 
with asthma, switchers to BF Spiromax versus BF 
Turbuhaler® reported fewer exacerbations (adjusted rate 
ratio (RR) 0.76;95% CI 0.60 to 0.99; p=0.044); were 
less likely to use high daily doses of SABA (adjusted 
OR 0.71;95% CI 0.52 to 0.98; p=0.034); used fewer 
SABA inhalers (adjusted RR 0.92;95% CI 0.86 to 0.99; 
p=0.019); and were more likely to achieve treatment 
stability (adjusted OR 1.44;95% CI 1.02 to 2.04; p=0.037). 
No significant differences in these end points were seen 
among patients with COPD.
Conclusions Among UK patients with asthma and COPD, 
real-world use of BF Spiromax was non-inferior to BF 
Turbuhaler in terms of disease control. Among patients 
with asthma, switching to BF Spiromax was associated 
with reduced exacerbations, reduced SABA use and 
improved treatment stability versus continuing on BF 
Turbuhaler.
IntrOduCtIOn  
Asthma and chronic obstructive pulmonary 
disease (COPD) are common respiratory 
conditions.1 2 Cornerstone asthma/COPD 
treatment consists of inhaled therapy with 
proven efficacy in randomised clinical trials 
(RCTs).3 4 In real life, however, incorrect 
inhaler use is common in patients with asthma 
or COPD, resulting in poor symptom control 
and worse outcomes.5 6 Specifically, critical 
inhaler errors were reported in a review of 
3660 patients;7 insufficient respiratory effort 
strengths and limitations of this study
 ► Clearly defined a priori hypothesis, end points and 
sample size.
 ► A non-selective patient population, obtained through 
the use of real-world data from validated databases 
of primary care patients, with sufficient follow-up 
period for observing relevant outcomes.
 ► Hospital admissions, accident and emergency (A&E) 
attendances and outpatient visits are not systemat-
ically recorded in primary care databases, and the 
applied definition to identify asthma-related hospital 
admissions or A&E events may have given rise to 
false positive events.
 ► Potential effects of inhaler technique on the reported 
outcomes could not be taken into account, as this 
would require close observation and communication 
with each patient as they demonstrated their inhaler 
technique.
 ► Observed differences in secondary outcomes could 
have arisen as a consequence of factors unrelated 
to the inhalers that might not have been captured in 
the data set.
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in dry-powder inhaler (DPI) users and actuation before 
inhalation in metered-dose inhaler (MDI) users were 
found to be associated with uncontrolled asthma.7 
In April 2014, marketing authorisation was granted for 
DuoResp® Spiromax® (Teva Pharmaceutical Industries, 
Petach Tikva, Israel), an inhaler containing a fixed-dose 
combination (FDC) of the inhaled corticosteroid (ICS) 
budesonide and the long-acting β2-agonist (LABA) formo-
terol (budesonide/formoterol (BF)). The Spiromax 
inhaler was designed to maximise ease of use, reliability 
of dosing and consistency of lung deposition8 9 in patients 
with asthma or COPD. Spiromax is a breath-actuated, 
multidose DPI that is similar in design and appearance 
to MDI, but uses a different internal configuration. Drug 
delivery is via the X-ACT® system, consisting of active 
metering (on opening the cap, an air pump transfers the 
drug from the drug reservoir to the dose cup) and cyclone 
separator technology (turbulent airflow), which breaks 
up the dry-powder blend and separates fine drug particles 
from larger lactose particles.8 Spiromax requires only one 
preparation step (opening the cap) and provides consis-
tent dose delivery across a broad range of inspiratory flow 
rates.8 9 Recent findings suggest that Spiromax is asso-
ciated with a reduced number of errors related to dose 
preparation, undertaking the steps needed to correctly 
deliver the dose during inhalation and handling the 
device after inhalation, as well as being easier for patients 
and healthcare professionals to use compared with other 
DPIs.10 11 BF Spiromax has demonstrated pharmacoki-
netic bioequivalence to BF Turbuhaler® (AstraZeneca UK 
Limited, UK) in healthy volunteers.12 13 A recent inde-
pendent study of COPD found BF Spiromax to have a 
faster onset of bronchodilation than BF Turbuhaler, likely 
due to differences in drug deposition between the two 
devices.14 However, evidence for the real-world effective-
ness of BF Spiromax in comparison with other inhalers in 
patients with asthma and/or COPD is lacking.
The current study was part of a multiphase assessment 
of real-world outcomes over 1 year in patients with asthma 
and/or COPD who switched to BF Spiromax compared 
with patients who remained on another device, using data 
from two UK primary care administrative databases. The 
primary objective of this phase of the study was to eval-
uate the non-inferiority of changing from another FDC 
inhaler to BF Spiromax versus continuing to use the orig-
inal FDC inhaler, in terms of achieving disease control, 
based on the risk domain control (RDC) algorithm; 
secondary objectives included the effects of the switch on 
the occurrence of moderate/severe exacerbations and 
respiratory-related hospitalisations, treatment stability 
and short-acting β2-agonist (SABA) use.
MethOds
Patients and study design
This was a matched, historic cohort study of patients with 
asthma and/or COPD using two validated primary care 
databases of patients in the UK, the Optimum Patient Care 
Research Database (OPCRD) and the Clinical Practice 
Research Datalink (CPRD).15 16 OPCRD is governed by 
The Anonymous Data Ethics Protocols and Transparency 
committee, commissioned by the Respiratory Effective-
ness Group.17 CPRD is a UK government research service, 
jointly supported by the National Institute for Health 
Research and the Medicines and Healthcare Products 
Regulatory Agency, that provides access to anonymised 
National Health Service (NHS) data. It operates under a 
range of UK and European laws as well as NHS and other 
guidelines.16 This study is registered with the European 
Network of Centres for Pharmacoepidemiology and Phar-
macovigilance (Register number EUPAS13238).18
The OPCRD and CPRD databases were searched 2010 
onwards to identify prescriptions of BF Spiromax, BF 
Turbuhaler and fluticasone propionate/salmeterol (FS) 
Accuhaler/Diskus (GlaxoSmithKline, Uxbridge, UK) 
in patients ≥18 years of age with asthma and/or COPD 
(figure 1). The OPCRD and CPRD data sets for this study 
were constructed separately and checked for overlap 
before pooling to exclude duplicate patients. Patients had 
to have at least 2 years of data, comprising a minimum of 
one baseline year and 1 year of outcome period. Patients 
were required to have at least three prescriptions for ICS/
LABA FDC (BF Spiromax, BF Turbuhaler or FS Accu-
haler® /Diskus®) therapy during the baseline period. 
Switch patients must have evidence of an initial BF 
Spiromax prescription in the outcome period as well as 
at least one supplementary prescription for BF Spiromax 
in the 1 year outcome period to ensure consistent usage. 
Likewise, patients remaining on their inhaler required 
at least one repeat prescription in the outcome period. 
We only included patients switching to BF Spiromax who 
were registered at practices considered to have a policy of 
BF Spiromax adoption or wholesale change (ie, the deci-
sion to switch inhaler was based on cost savings instead of 
clinical reasons). Such practices were identified as those 
at which at least five patients changed to BF Spiromax 
within a 3-month period. The current study includes only 
patients who stayed on BF Turbuhaler or switched from 
BF Turbuhaler to BF Spiromax, due to the low number 
of patients who switched from FS Accuhaler/Diskus to 
BF Spiromax. The date of the first prescription of BF 
Spiromax or the (matched) date of the repeat prescrip-
tion for BF Turbuhaler in the control arm was the index 
date. The recommended dosing instructions of BF Turbu-
haler and BF Spiromax in adults are the same (asthma: 
one to two inhalations twice daily; COPD: two inhalations 
twice daily), and we observed no significant differences 
in prescribed dose between BF Spiromax and BF Turbu-
haler in the disease groups.
Patients with asthma were required to have a diag-
nostic code (Read code)19 for asthma and/or at least two 
prescriptions for asthma therapy during the baseline year, 
and to have no other chronic respiratory disease diag-
nosis. Patients with COPD were required to be at least 
40 years of age at first prescription for BF Spiromax or 
the matching BF Turbuhaler prescription, and to have 
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a diagnostic code for COPD and a postbronchodilator 
FEV1/FVC <0.70 consistent with the criteria for inclusion 
in the UK register of patients with COPD (Quality and 
Outcomes Framework). The subgroup of patients with 
only an asthma diagnosis is referred to henceforth as the 
asthma group. The patients with a COPD diagnosis (with 
or without an asthma diagnosis) are henceforth referred 
to as the COPD group.
Outcome measures
The primary outcome was disease control as assessed 
by RDC, a composite measure that has been used in 
several similar matched historical cohort studies to define 
absence of exacerbations.20–23 To achieve RDC in this 
study, patients must not have an asthma/COPD-related 
hospital admission, an asthma/COPD-related accident 
and emergency (A&E) attendance or a course of oral 
corticosteroids (OCS) during the outcome period. In 
addition, patients in the COPD group must not have 
received antibiotics for a lower respiratory tract infection 
(LRTI).
Secondary outcomes included the number of 
moderate/severe exacerbations and hospitalisations, and 
change in treatment stability. A moderate/severe exacer-
bation (for COPD) or severe exacerbation (for asthma) 
was defined following the American Thoracic Society/
European Respiratory Society Task Force position state-
ments.24 Lower respiratory hospitalisations were identi-
fied and classified as follows: definite hospitalisations were 
Figure 1 Patient flow diagram (prior to matching). BF, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; 
CPRD, Clinical Practice Research Datalink; FS, fluticasone propionate/salmeterol; ICS, inhaled corticosteroid; LABA, long-
acting β2-agonist; OPCRD, Optimum Patient Care Research Database. 
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those with a lower respiratory code, including asthma and 
LRTI codes; or a generic hospitalisation Read code that 
has been recorded on the same day as a lower respira-
tory consultation; definite+probable hospitalisations were 
those occurring within a 7-day window (either side of the 
hospitalisation date) of a lower respiratory Read code. 
Adequate treatment stability was defined as achieving 
RDC and no increase in dose, change in delivery device, 
and change in type of ICS and/or use of LABAs, theoph-
ylline, long-acting muscarinic antagonists, or leukot-
riene receptor antagonists.22 Additional outcomes were 
SABA usage, which was expressed as average daily SABA 
dosage during the outcome year and calculated from 
prescriptions as ((Count of inhalers × doses in pack × µg 
strength)/365), and a pneumonia event which was defined 
as having a Read coded diagnosis (probable pneumonia), 
or a Read coded diagnosis with a hospital admission or 
chest X-ray within 1 month (definite pneumonia).
statistical analyses
It was estimated that 349 patients would have 90% power 
to demonstrate non-inferiority of BF Spiromax and BF 
Turbuhaler for achieving RDC, at a one-sided signifi-
cance level of 0.050. For the calculation, an expected 
difference in proportions of zero was used, assuming 
that the proportion of discordant pairs was 0.458. This 
assumption was based on previous studies showing that 
a weighted average of 71.6% of patients with asthma and 
COPD prescribed FDC therapy have no exacerbations 
over a 1-year period.25 26
Descriptive statistics of all baseline demographic char-
acteristics, comorbidities, medication use, indicators of 
disease severity and other patient characteristics were 
computed separately for the patients in the BF Spiromax 
and BF Turbuhaler groups and for patients in the asthma 
and COPD groups. In cases where multiple observations 
existed for a patient, one was randomly selected. Contin-
uous variables were summarised using the number of 
non-missing observations, percentage of non-missing 
observations, mean, SD, median and IQR (difference 
between the 25th and 75th centiles), and a p value for the 
Kruskal-Wallis equality-of-populations rank test. Binary 
and categorical variables were summarised using the 
percentage of non-missing observations, the frequency 
and percentages (based on the non-missing sample size) 
of observed levels, and a p value for the Pearson's χ2 test 
of independent categories.
Patients who switched to BF Spiromax were compared 
with matched controls who stayed on BF Turbuhaler. 
Mixed matching was performed 1:3 so that each BF 
Spiromax patient would be matched with up to three 
patients who remained on BF Turbuhaler (see supple-
mentary methods in appendix for a full description 
of the mixed matching process). Mixed matching was 
performed to increase precision of the effect estimates. 
Because the analyses were conducted on all of the matched 
patients, which could introduce residual confounding 
due to imbalanced matching ratios, a sensitivity analysis 
was performed in which the outcome analyses were also 
performed in the subpopulation of patients in the BF 
Spiromax arm with exactly three matched patients in the 
BF Turbuhaler arm. Matching was performed using the 
most relevant confounders which were identified based 
on baseline imbalance and bias potential in relation to 
the primary outcome. For asthma, these confounders 
included age, gender, number of antibiotic courses, 
number of OCS courses, Global Initiative for Asthma 
control categories, number of exacerbations and RDC; 
matching confounders for COPD included age, gender, 
drug therapy, ICS average daily dose, number of antibi-
otic courses, number of exacerbations and Global Initia-
tive for Chronic Obstructive Lung Disease risk categories. 
Baseline imbalance was assessed using the standardised 
mean difference (SMD), which, unlike a p value, is not 
affected by the number of observations in a sample,27 28 
and provides information on the size of the difference. 
An SMD of ≤10% was assumed to represent sufficient 
balance between the arms,29 and the formula used is 
presented in the supplementary methods in appendix. 
Bias potential is the degree to which the observed associa-
tion between the exposures of interest and the outcome is 
affected by conditioning on another variable; the formula 
is presented in the supplementary methods in appendix. 
A sensitive bias potential cut-off of ≥2% was used for this 
study.
Baseline variables with highest bias potential that were 
also insufficiently balanced were presented to a panel 
of experts for final selection. Following matching, the 
process was repeated in the matched sample to identify 
any residual confounding.
After mixed matching, conditional logistic regression 
of the between-patient difference in the primary outcome 
was performed to provide a 95% CI with which to assess 
non-inferiority. Analyses were undertaken for the patients 
in the asthma and COPD groups combined, as well as by 
disease group. The model was adjusted for baseline vari-
ables that remained with bias potential after matching. 
Non-inferiority was claimed if the lower bound of the 
95% CI for the primary end point (RDC) was above −10%, 
a difference widely regarded as clinically important for 
many outcomes in respiratory studies,30 31 and used previ-
ously in similar real-life studies of patients in primary care 
settings.22 23 If non-inferiority was achieved, superiority 
was tested.
Secondary outcomes were analysed in the matched 
sample and adjusted for baseline variables that remained 
with bias potential after matching, and reported as 
conditional rate ratios (RRs) or ORs with their 95% CIs. 
Number of exacerbations and hospitalisations were anal-
ysed in the matched sample using conditional Poisson 
regression to obtain estimates of relative rates. Treat-
ment stability was analysed in the matched sample using 
conditional logistic regression, and SABA usage was anal-
ysed in the matched sample using conditional ordinal 
logistic regression, after the SABA average daily dose was 
categorised.
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All statistical analyses were conducted using Stata 
MP6 V.12 and Stata SE V.14 (StataCorp, College Station, 
Texas, USA). A statistically significant result was defined 
as p<0.05.
Patient and public involvement
No patients or public were involved in the design or 
conduct of this retrospective database study.
results
study population
Overall, 420 patients switched to BF Spiromax (figure 1). 
Of the patients who used BF Turbuhaler, 410 switched 
to BF Spiromax and 49 386 remained on BF Turbuhaler. 
Baseline characteristics of these unmatched patients 
are shown in supplementary table 1, where imbalanced 
covariates (SMD >10%) for asthma include mean age, 
drug therapy, ICS average daily dose and number of 
exacerbations in baseline years; those for COPD include 
smoking status, drug therapy and ICS average daily dose.
For the matched analysis, a total of 385 patients switching 
to BF Spiromax were analysed; a total of 1091 patients 
who stayed on BF Turbuhaler were matched to the switch 
patients (figure 1). Twenty-five patients who switched back 
to BF Turbuhaler or to another FDC ICS/LABA were not 
included in the analysis. In the baseline characteristics of 
the matched patients, covariates with SMD >10% in the 
asthma group were body mass index and ischaemic heart 
disease; for COPD they were smoking status, ischaemic 
heart disease, heart failure, number of exacerbations and 
number of acute OCS courses (table 1).
Outcomes analyses
Descriptive statistics of disease outcomes in the matched 
patients are shown in table 2. The FDC average daily 
dose was numerically lower among patients using BF 
Spiromax in the asthma group (382.1 µg vs 505.3 µg) and 
mean per cent RDC was higher among patients using 
BF Spiromax in both the asthma (73.1% vs 68.0%) and 
COPD (40.2% vs 37.1%) groups (table 2).
The lower bound of the 95% CI of the adjusted 
percentage difference in the frequency of achieving RDC 
in the combined population was −0.3%, meeting the 
criterion for non-inferiority of switching to BF Spiromax 
compared with continuing on BF Turbuhaler (figure 2). 
Although a higher proportion of patients achieved RDC 
in the group that switched to BF Spiromax compared 
with patients who stayed on BF Turbuhaler, the difference 
was not statistically significant, and the mean between-
group difference was less than the 10% considered to be 
clinically relevant.22 23 30 31 In the sensitivity analysis where 
only BF Spiromax switchers that had three matched 
controls were used, a significant difference was shown in 
the combined patients group (adjusted % difference 8.3; 
95% CI 1.0% to 15.6%; p=0.025) (data not shown). In the 
sensitivity analysis, the adjusted percentage difference 
was nearly 10% in the COPD group but there was a wide 
CI (adjusted % difference 9.9; 95% CI −2.4% to 22.2%; 
p=0.114). Similarly, in the asthma group, the adjusted 
percentage difference was 6.5% (95% CI −2.7% to 15.7%; 
p=0.168). The conditional logistic regression model in all 
matched patients showed an adjusted OR of 1.31 (95% CI 
0.99 to 1.73; p=0.061) for BF Spiromax versus BF Turbu-
haler for RDC, which did not achieve statistical signifi-
cance. However, in the sensitivity analysis, the OR of 1.41 
was statistically significant (95% CI 1.05 to 1.90; p=0.022) 
(data not shown).
Secondary outcomes shown are expressed as adjusted 
conditional RRs (figure 3a) and ORs (figure 3b) sepa-
rately for patients with asthma and those with COPD. 
Among patients with asthma, switchers to BF Spiromax 
versus BF Turbuhaler reported fewer exacerbations, were 
less likely to use high amounts of SABA daily dose, used 
fewer SABA inhalers and were more likely to achieve 
treatment stability. Among patients with COPD, no signif-
icant differences in these end points were seen between 
those who switched to BF Spiromax and those staying 
on BF Turbuhaler. CIs for patients who switched to BF 
Spiromax show a trend effect for lower risk of being on 
high-dose SABA therapy and reduction in use of SABA 
inhalers in the COPD group. In the combined patients 
group, significance among switchers to BF Spiromax was 
noted in SABA average daily dose (OR 0.70; 95% CI 0.53 
to 0.94; p=0.017), reduction in use of SABA inhalers (RR 
0.94; 95% CI 0.89 to 0.99; p=0.012) and improved treat-
ment stability (OR 0.74; 95% CI 0.56 to 0.99; p=0.041).
dIsCussIOn
This study, the first to compare the real-world effective-
ness of switching to the BF Spiromax inhaler from BF 
Turbuhaler, found that among 253 patients with asthma 
and 132 patients with COPD, BF Spiromax showed non-in-
feriority with respect to achievement of disease control 
to BF Turbuhaler in matched patients with asthma and/
or COPD. In the primary analysis in the combined popu-
lation, patients who switched to BF Spiromax had 31% 
higher odds of achieving RDC compared with those who 
remained on BF Turbuhaler; however, this finding did 
not meet the threshold for statistical significance.
Patients in the asthma group who switched to BF 
Spiromax had significantly reduced SABA use, fewer exac-
erbations and greater treatment stability compared with 
matched patients who remained on BF Turbuhaler. Some 
of the observed reductions in SABA use associated with 
BF Spiromax may have arisen as a result of patients using 
their new device as a reliever medication in addition to its 
use as maintenance therapy. The use of BF in a single-in-
haler maintenance and quick-relief therapy regimen has 
been recommended as an improved method of adminis-
tering ICS/LABA therapy.32 33 However, the recommen-
dations are not device-specific; as such, SABA use was not 
expected to differ between switchers to Spiromax and 
those who remained on Turbuhaler. The difference may 
be partially explained by the greater resemblance to an 
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MDI device of Spiromax compared with Turbuhaler. No 
significant differences between patients who switched 
and those who did not were observed in the COPD group. 
This might be partly caused by lower statistical power in 
the COPD group, which included approximately half 
the number of patients as in the asthma group, and 
by the general notion that the reduction in exacerba-
tion frequency with ICS is less in COPD compared with 
asthma.34 Another factor that could have contributed is 
the much older age (~15 years) of patients in the COPD 
group. Age is a proxy for many health-related charac-
teristics, and there is evidence of a negative correlation 
between advancing age and correct inhaler technique 
across MDI and the varying DPI devices.35
Switching asthma medications is often necessary for 
several reasons, including regaining or achieving asthma 
control or to constrain healthcare costs. Due to the retro-
spective design of our study, reasons for switching inhaler 
were not captured. However, we selected BF Spiromax 
patients registered at practices considered to have a policy 
of BF Spiromax adoption or wholesale change. While we 
cannot exclude some inhaler switches being induced by 
clinical reasons, the requirement for practices to have at 
least five patients switch to BF Spiromax within a 3-month 
Table 2 Descriptive statistics of disease outcomes in the matched cohorts of patients.
Outcomes
Patients with asthma Patients with COPD
BF Spiromax
(n=253)
BF Turbuhaler 
(n=743)
BF Spiromax
(n=132)
BF Turbuhaler 
(n=348)
% Risk domain control 73.1 68.0 40.2 37.1
No. of exacerbations (SD) 0.3 (0.7) 0.4 (0.7) 1.1 (1.4) 1.0 (1.4)
% Treatment stability 72.7 66.9 39.4 37.1
SABA average daily dose (SD) 1.4 (1.9) 1.5 (2.9) 2.6 (2.9) 2.4 (2.3)
No. of SABA inhalers (SD) 5.1 (6.8) 5.5 (10.7) 9.5 (11.0) 8.7 (8.5)
No. of antibiotics prescriptions (SD) 0.2 (0.7) 0.4 (0.8) 0.7 (1.1) 0.8 (1.1)
No. of acute OCS courses (SD) 0.3 (0.7) 0.3 (0.7) 1.0 (1.7) 0.9 (1.3)
FDC ICS average daily dose (SD) 382.1 (351.3) 505.3 (585.0) 555.3 (427.1) 561.8 (646.1)
No. of FDC inhalers (SD) 14.0 (8.9) 10.8 (5.6) 15.0 (6.7) 11.9 (5.4)
No. of respiratory A&E attendances (SD) 0.0 (0.1) 0.0 (0.1) 0.0 (0.2) 0.1 (0.4)
No. of probable respiratory inpatient 
hospitalisations (SD)
0.0 (0.1) 0.0 (0.1) 0.1 (0.4) 0.1 (0.5)
No. of definite respiratory inpatient 
hospitalisations (SD)
0.0 (0.1) 0.0 (0.1) 0.0 (0.3) 0.1 (0.4)
% Probable pneumonia* 0.0 0.0 3.0 2.3
% Definite pneumonia* 0.0 0.0 2.3 0.6
A&E, accident and emergency; BF, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FDC, fixed-dose combination; ICS, 
inhaled corticosteroid; OCS, oral corticosteroid; SABA, short-acting β2 agonist.
*A pneumonia event was defined as having a Read coded diagnosis (probable pneumonia), or a Read coded diagnosis with a hospital 
admission or chest X-ray within 1 month (definite pneumonia).
Figure 2 Frequency of achievement of RDC in patients switching to BF Spiromax and those continuing on BF 
Turbuhaler. BF, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; RDC, risk domain control. 
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period means that in our view it is probable that many 
of the switches to BF Spiromax at these centres were 
driven by economic rationales. Thus, it is expected that 
any differences between treatments in our study result 
from the switch in inhalers rather than improvement in 
poor disease control. A switch to a different inhaler may 
Figure 3 Clinical outcomes expressed as adjusted conditional (A) rate ratios (95% CI) and (B) ORs (95% CI), among patients 
switching to BF Spiromax versus continuing on BF Turbuhaler in the matched analysis. *Model did not converge in the asthma 
group. BF, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; RDC, risk domain control; SABA, short-
acting β2 agonist. 
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potentially increase patient-practice contact, in terms of 
additional evaluation and teaching of inhaler technique, 
which may confound the results. However, in a pilot study 
which has been published only in abstract form,36 76% 
of 114 patients were switched to BF Spiromax without 
consultation, suggesting that any confounding created 
by additional physician teaching for those who switched 
versus those remaining on original therapy was limited 
in the overall patient population. Indeed, previous find-
ings have shown that most patients with asthma who have 
had their inhaler device switched without their consent 
believed that cost issues were a factor.37 As such, it is likely 
that many of the switches experienced by our patient 
cohort took place at least in part for economic reasons.
The results observed in this real-world study are consis-
tent with previous evidence gained from RCTs where 
BF Spiromax was found to have similar efficacy to BF 
Turbuhaler.38 The suggestion of potential superiority 
on secondary outcome measures in the current study, a 
result which was not seen in RCTs, might plausibly reflect 
differences in ease of use and/or adherence between the 
inhalers when prescribed in routine care. Patients partici-
pating in respiratory RCTs usually represent only between 
1% and 5% of the true population of patients with asthma 
or COPD39 and the proportion of patients with COPD 
in primary care who would be eligible for inclusion in 
recent large pharmaceutically sponsored COPD studies 
has ranged from 17% to 42%.40 In addition, adherence 
to treatment in real-world observational studies is usually 
much lower than in RCTs.41 Moreover, proper inhaler 
technique is often artificially high in clinical trials because 
of patient selection, extensive training, and close moni-
toring, which may explain why minimal differences in 
outcomes between devices have been observed in RCTs.42 
However, in daily practice, patients’ differential ability 
to correctly use their inhaler may result in larger differ-
ences in health outcomes. Previous studies have shown 
that study participants and healthcare professionals 
find it easier to learn how to use the Spiromax inhaler 
correctly, compared with other DPIs.10 11 Furthermore, 
patients are able to achieve slightly higher peak inspira-
tory flow rates with the Spiromax inhaler compared with 
the Turbuhaler.43
This study had a clearly defined a priori hypothesis, 
end points and sample size, as is recommended for this 
type of observational research.44 A particular strength was 
the non-selective patient population obtained through 
the use of real-world data from validated databases of 
primary care patients. The size and scope of these data-
bases allowed for the collection of important clinical 
variables and a sufficient follow-up period for observing 
relevant outcomes. In addition, the study’s time horizon 
of 1 year has minimised the impact of potential seasonal 
differences in disease activity.45 Overall, the study was well 
powered to investigate the primary outcome which was 
RDC of disease.
The inclusion of matched patients in our analysis of 
RDC risked introducing residual confounding due to 
imbalanced matching ratios. We therefore performed 
a sensitivity analysis in the subpopulation of patients in 
the BF Spiromax arm with exactly three matched patients 
in the BF Turbuhaler arm. Compared with patients who 
remained on BF Turbuhaler, patients who switched to BF 
Spiromax had 31% and 41% higher odds of achieving 
RDC in the primary analysis and sensitivity analysis, 
respectively, with the difference reaching statistical 
significance in the sensitivity analysis only. Regardless of 
whether significance was achieved, the difference in odds 
with BF Spiromax versus BF Turbuhaler is quite similar 
between the primary and sensitivity analyses, supporting 
the overall validity of our assumptions for the effect of 
BF Spiromax versus BF Turbuhaler on achieving disease 
control.
Limitations of the study are important to note. The use 
of databases to evaluate outcomes depends on the infor-
mation registered, which is for clinical and routine use 
rather than research purposes. Possible issues include 
the fact that hospital admissions, A&E attendances 
and outpatient visits are not systematically recorded in 
primary care databases and the applied definition to iden-
tify asthma-related hospital admissions or A&E events 
may give false positive events. However, this limitation 
would apply equally to both groups. In addition, inhaler 
technique could not be taken into account for this study 
as this would require close observation and communica-
tion with each patient as they demonstrated their inhaler 
technique. Regarding the secondary outcomes, we 
cannot rule out the possibility that the observed differ-
ences were caused by factors unrelated to the inhalers, as 
patients who switched to BF Spiromax may have differed 
from non-switchers in ways not captured in our data set. 
Comparison with other ICS/LABA FDCs would have 
been useful to determine any differences attributable to 
pharmacological effect; however, there were insufficient 
patient numbers for such comparisons. An important 
limitation in observational studies is the potential for 
confounding of the associations arising from systematic 
differences between the patients being compared. In 
this study, confounding was minimised where possible 
using matching techniques to create cohorts that were 
comparable in terms of important demographic and 
clinical characteristics as recommended by the Respi-
ratory Effectiveness Group.44 Multivariate models were 
adjusted by those variables that continued to confound 
the associations of interest after matching. However, in 
the COPD group, due to a limited number of patients, 
only a restricted set of variables could be used for 
matching and model adjustment. Therefore, we cannot 
ensure confounding of the association of interest was 
sufficiently addressed in this group. Furthermore, as 
previously discussed, the selection of patients from prac-
tices which were required to have at last five switchers 
to BF Spiromax in a 3-month period could potentially 
have introduced a bias in favour of practices with greater 
than average asthma/COPD expertise and involvement 
in care of patients with asthma/COPD.
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This real-world analysis showed that switching from BF 
Turbuhaler to BF Spiromax was associated with no loss of 
symptom control and may be beneficial in some patients. 
These data validate, in a real-world population of patients 
with asthma and COPD and clinical setting, similar effi-
cacy to that previously demonstrated in an RCT.38 Such 
validation is important for primary practitioners as it 
provides reassurance that BF Spiromax is effective in real-
world primary care patients, and not just in the carefully 
selected and closely monitored cohorts of patients typical 
of RCTs. It should however be noted that periodical 
assessments of adherence, motivation and inhaler tech-
nique are still likely to be required to ensure that optimal 
inhaler use is maintained in the long term.46–51 Further 
research may be needed to assess the extent to which the 
results of this analysis are generalisable to patients outside 
of the UK.
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